← FDA DRUG APPROVALS

FDA ANDA · ANDA090560

NAFCILLIN

nafcillin sodium

Sponsor: ANTIBIOTICE

APPLICATION
ANDA090560
TYPE
ANDA
ORIGINAL APPROVAL
2011-10-03
LATEST ACTION
2022-12-06
ROUTE
INTRAMUSCULAR, INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

NAFCILLIN SODIUMPrescription
NAFCILLIN SODIUM EQ 1GM BASE/VIAL · INJECTABLE · INJECTION
NAFCILLIN SODIUMPrescription
NAFCILLIN SODIUM EQ 2GM BASE/VIAL · INJECTABLE · INJECTION

Approval history

2022-12-06Labeling · Supplement 7 · standardAP
2021-01-27Labeling · Supplement 5 · standardAP
2021-01-27Labeling · Supplement 3 · standardAP
2011-10-03OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →